Navigation Links
RainEarth Obtains Patent Approvals for Its Core Technology
Date:6/26/2009

BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc. (OTC Bulletin Board: RNER; "the Company"), announced that its contractual partner in China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"), has obtained patent approvals for its core technology, which consists of products that aid in manufacturing blood dialysis.

China RainEarth applied for and was approved for patents for its core technology with the State Intellectual Property Office of P.R.C. (SIPO). These patents include:

    -- Mass production method for hollow fiber membranes
    -- Quick cleaning equipment for hollow fiber membranes
    -- Quick drying equipment for hollow fiber membranes
    -- Device for adjusting dry spinning range in hollow fiber membrane
       dry-wet spinning and control condensation bath process concentration
       control
    -- Manufacturing technique for blended PES hollow fiber dialysis membrane
    -- Synthetic hollow fiber membrane continuous spinning device
    -- Hollow fiber membrane porous spinneret component
    -- Hollow fiber tube-in-orifice spinneret

"These patents will not only help to ensure that competitive prices are maintained in the production of these materials, but also that the highest level of quality possible is provided. We have also put RainEarth in a strong market position by applying for these patents before our competitors. With these technologies and sufficient funds, we can increase our production from 150,000 blood dialysis to between 1.5-3.2 million. This will generate revenue in the area of $12-32 million (USD)," said Mr. Zhu, CEO of the Company.

About the Company

RainEarth Inc. (formerly Gold Rock Resources Inc., the "Company") was incorporated in the State of Nevada on March 14, 2006. The Company is a developing stage company that initially engages in the search for mineral deposits or reserves.

On March 25, 2009, the Company and China RainEarth, a company organized and existing under the laws of the People's Republic of China, entered into a Business Cooperation Agreement (the "Agreement") for a term of twenty years. The purpose of the Agreement is to jointly conduct Hollow Fiber Membrane Materials' application and manufacturing business in China (the "Business"). The first product that utilizes this technology is blood dialyzer.

The Company will provide Advice and assistance relating to development of marketing and consultancy services, particularly as related to the Business. China RainEarth will give 60% of its revenue after deduction of direct operating costs, expenses and taxes to the Company in consideration of the Company's services.

Forward-looking statements

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements involve risks and uncertainties including, but not limited to, economic and political factors; developments of the Chinese and North American markets and changes in regulatory matters; our business strategies and future plans of operations; the market acceptance and amount of sales of our products and services; our historical losses; the competitive environment within the industries in which we compete; and our ability to raise additional capital, currently needed for expansion. The Company cautions that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to several important factors.

    For more information, please contact:

     RainEarth Inc.
     Public Relationship Department
     Tel:   +852-3005-7220
     Email: Investor@rainearth.net

'/>"/>
SOURCE RainEarth Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Gold Rock Changed Name to RainEarth Inc. and Launches New English Web Site
2. RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment
3. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
4. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
5. Aspreva obtains shareholder approval for acquisition by Galenica
6. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
7. DRAXIS Obtains Interim Order for Proposed Arrangement
8. DRAXIS Obtains Final Order for Proposed Arrangement
9. China Medicine Corporation Obtains Australian Patent for rADTZ
10. William F. McMurry - Lead Class Counsel Obtains $16.4 Million Settlement for Elderly Clients
11. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: